• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[缺氧癌细胞放射增敏的实验研究]

[Experimental studies on radiosensitization of hypoxic cancer cells].

作者信息

Omura M

出版信息

Nihon Sanka Fujinka Gakkai Zasshi. 1983 Nov;35(11):1972-80.

PMID:6663130
Abstract

Misonidazole was histologically evaluated as a hypoxic cell radiosensitizer to a transplantable human cervical cancer in nude mice (Yumoto Strain). Acute exposure of X-ray (Lineac, a 1,000 rad dose) was applied to the cervical cancer. Tumor Volume (T.V. growth curve). Radiation alone induced an 8-10 day growth delay, but radiation therapy with Misonidazole induced a 10-12 day growth delay. Tumor Cord (T.C.). This idea originated with Thomlinson and Gray. They found that the radius of a tumor cord was always same. On the radiation therapy with Misonidazole, the tumor cords decreased faster than with radiation therapy alone. Tumor cellular Density (T.D.). This is the cell population per unit of area. We separated the tumor cords with two blocks, one near and one far from the blood vessel. T.D. decreased faster in the case of radiation with Misonidazole, and on the far square, radiation effectiveness was more obvious than on the near one. In addition, a histological examination proved that the Misonidazole affected hypoxic elements of the tumor, and this finding was proved in 48 hours after radiation. But aerobic elements of the tumor survived and were slightly changed histologically. In conclusion, Misonidazole proved to be an effective hypoxic cell sensitizer for human cervical cancer in radiation therapy.

摘要

在裸鼠(汤本株)移植的人类宫颈癌中,对米索硝唑进行了组织学评估,以确定其作为乏氧细胞放射增敏剂的效果。对宫颈癌进行了X射线(直线加速器,1000拉德剂量)的急性照射。肿瘤体积(T.V.生长曲线)。单独放疗导致肿瘤生长延迟8 - 10天,但米索硝唑联合放疗导致肿瘤生长延迟10 - 12天。肿瘤索条(T.C.)。这个概念由汤姆林森和格雷提出。他们发现肿瘤索条的半径总是相同的。使用米索硝唑进行放疗时,肿瘤索条比单独放疗时减少得更快。肿瘤细胞密度(T.D.)。这是单位面积内的细胞数量。我们用两个区域分隔肿瘤索条,一个靠近血管,一个远离血管。在使用米索硝唑放疗的情况下,T.D.下降得更快,并且在远离血管的区域,放疗效果比靠近血管的区域更明显。此外,组织学检查证明米索硝唑影响肿瘤的乏氧成分,并且这一发现于放疗后48小时得到证实。但是肿瘤的有氧成分存活下来,并且在组织学上有轻微变化。总之,米索硝唑被证明是人类宫颈癌放疗中一种有效的乏氧细胞增敏剂。

相似文献

1
[Experimental studies on radiosensitization of hypoxic cancer cells].[缺氧癌细胞放射增敏的实验研究]
Nihon Sanka Fujinka Gakkai Zasshi. 1983 Nov;35(11):1972-80.
2
[Flow-microfluorometric studies on the effect of misonidazole as a radiosensitizer for human uterine cervical carcinoma transplanted to nude mice].[丝裂霉素作为人子宫颈癌移植到裸鼠体内的放射增敏剂作用的流式微量荧光研究]
Nihon Sanka Fujinka Gakkai Zasshi. 1983 Dec;35(12):2368-76.
3
The effect of hypoxic radiosensitizer after mild hyperthermia in C3H mammary carcinoma.轻度热疗后低氧放射增敏剂对C3H乳腺癌的影响。
Tokai J Exp Clin Med. 1984 Oct;9(4):331-7.
4
[Treatment with misonidazole and high voltage irradiation of xenotransplanted human carcinomas in nu/nu mice with thymic aplasia].[米索硝唑治疗及对胸腺发育不全的裸鼠体内异种移植的人类癌进行高压照射]
Strahlentherapie. 1982 Aug;158(8):498-503.
5
Studies in radiosensitizing effects of misonidazole and SR-2508 on C3H/He mouse mammary tumors.米索硝唑和SR-2508对C3H/He小鼠乳腺肿瘤的放射增敏作用研究。
Radiat Med. 1984 Jan-Mar;2(1):71-5.
6
Influence of misonidazole on the radiosensitivity of transplantable transitional cell bladder carcinoma in mice.米索硝唑对小鼠可移植性移行细胞膀胱癌放射敏感性的影响。
Invest Urol. 1981 Jul;19(1):14-6.
7
[Clinical evaluation of hypoxic cell sensitizer (Misonidazole)].[乏氧细胞增敏剂(米索硝唑)的临床评价]
Gan To Kagaku Ryoho. 1984 Jun;11(6):1225-30.
8
[Clinical trials of hypoxic cell sensitizer misonidazole].[乏氧细胞增敏剂米索硝唑的临床试验]
Gan No Rinsho. 1983 May;29(6):718-25.
9
Radiosensitization, pharmacokinetics, and toxicity of a 2-nitroimidazole nucleoside (RA-263).一种2-硝基咪唑核苷(RA-263)的放射增敏作用、药代动力学及毒性
Radiat Res. 1986 Feb;105(2):227-39.
10
A phase III randomized study of misonidazole plus radiation vs. radiation alone for cervix cancer.一项关于米索硝唑联合放疗与单纯放疗治疗宫颈癌的III期随机研究。
Radiother Oncol. 2004 Mar;70(3):295-9. doi: 10.1016/j.radonc.2003.11.018.